Why Choose Shobha Life Sciences for Dapagliflozin?
WHO-GMP Certified Facilities
Manufactured in certified units that uphold international regulatory protocols, ensuring consistent product quality.Proven API Excellence
The Dapagliflozin API is processed with precision to ensure high purity, stability, and bioavailability—essential attributes for therapeutic efficacy.Hyderabad-Based Infrastructure
Located in the pharmaceutical hub of India, Shobha Life Sciences boasts scalable production units, R&D capabilities, and logistics suited for both domestic and international supply chains.Robust Regulatory Documentation
From COA, MSDS, to DMF support, Shobha offers full documentation to facilitate seamless product registrations and approvals.Strong R&D and Innovation Track Record
Their dedicated research team works on 15–20 API projects annually, accelerating development and maintaining competitive pricing for global markets.
Applications of Dapagliflozin API
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in treating Type 2 Diabetes Mellitus and reducing cardiovascular risks. API buyers and formulation manufacturers require reliable sources that guarantee:
Consistent Assay Values
Controlled Impurities
Excellent Batch Reproducibility
Long-Term Stability Profiles
Shobha Life Sciences ensures all these aspects with its integrated QA-QC systems and modern analytical equipment.
Ideal Partner for Global API Buyers
Whether you’re a domestic formulation company or an international bulk buyer, Shobha Life Sciences delivers:
Flexible batch sizes
Regulatory-ready support
Transparent pricing
On-time global logistics
Their proactive customer support team ensures smooth onboarding and scale-up processes from inquiry to delivery.
Conclusion
Shobha Life Sciences is more than just a Dapagliflozin API manufacturer in Hyderabad—it's a strategic partner committed to quality, compliance, and innovation. With its advanced facilities and a customer-centric approach, the company continues to serve as a trusted supplier to pharmaceutical leaders across the globe.
